

# Amanda Haymond

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6966456/publications.pdf>

Version: 2024-02-01

15  
papers

275  
citations

1163117

8  
h-index

996975

15  
g-index

16  
all docs

16  
docs citations

16  
times ranked

406  
citing authors

#	ARTICLE	IF	CITATIONS
1	Protein biomarkers for subtyping breast cancer and implications for future research. <i>Expert Review of Proteomics</i> , 2018, 15, 131-152.	3.0	63
2	Synthesis and Bioactivity of $\hat{1}^2$ -Substituted Fosmidomycin Analogues Targeting 1-Deoxy- $\hat{d}$ -xylulose-5-phosphate Reductoisomerase. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 2988-3001.	6.4	34
3	Structure-Activity Relationships of the MEPicides: N-Acyl and O-Linked Analogs of FR900098 as Inhibitors of Dxr from <i>Mycobacterium tuberculosis</i> and <i>Yersinia pestis</i> . <i>ACS Infectious Diseases</i> , 2016, 2, 923-935.	3.8	27
4	Design of potential bisubstrate inhibitors against <i>Mycobacterium tuberculosis</i> (Mtb) 1-deoxy-d-xylulose 5-phosphate reductoisomerase (Dxr) – evidence of a novel binding mode. <i>MedChemComm</i> , 2013, 4, 1099.	3.4	26
5	MEPicides: $\hat{1}^{\pm}$ , $\hat{1}^2$ -Unsaturated Fosmidomycin Analogues as DXR Inhibitors against Malaria. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8847-8858.	6.4	26
6	The effect of chain length and unsaturation on Mtb Dxr inhibition and antitubercular killing activity of FR900098 analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 649-653.	2.2	24
7	Kinetic Characterization and Allosteric Inhibition of the <i>Yersinia pestis</i> 1-Deoxy-D-Xylulose 5-Phosphate Reductoisomerase (MEP Synthase). <i>PLoS ONE</i> , 2014, 9, e106243.	2.5	18
8	Protein painting, an optimized MS-based technique, reveals functionally relevant interfaces of the PD-1/PD-L1 complex and the YAP2/ZO-1 complex. <i>Journal of Biological Chemistry</i> , 2019, 294, 11180-11198.	3.4	14
9	Seropositivity of COVID-19 among asymptomatic healthcare workers: A multi-site prospective cohort study from Northern Virginia, United States. <i>The Lancet Regional Health Americas</i> , 2021, 2, 100030.	2.6	10
10	Proteomics for cancer drug design. <i>Expert Review of Proteomics</i> , 2019, 16, 647-664.	3.0	9
11	VOC fingerprints: metabolomic signatures of biothreat agents with and without antibiotic resistance. <i>Scientific Reports</i> , 2020, 10, 11746.	3.3	8
12	Durability of Viral Neutralization in Asymptomatic Coronavirus Disease 2019 for at Least 60 Days. <i>Journal of Infectious Diseases</i> , 2021, 223, 1677-1680.	4.0	4
13	Serological Testing for COVID-19 Disease: Moving the Field of Serological Surveillance Forward. <i>Journal of Applied Laboratory Medicine</i> , 2021, 6, 584-587.	1.3	4
14	A high-throughput screening campaign to identify inhibitors of DXP reductoisomerase (IspC) and MEP cytidyltransferase (IspD). <i>Analytical Biochemistry</i> , 2018, 542, 63-75.	2.4	3
15	Next-Generation Techniques for Determination of Protein-Protein Interactions: Beyond the Crystal Structure. <i>Current Pathobiology Reports</i> , 2019, 7, 61-71.	3.4	2